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Background
General practitioners (GPs) play an important role in
diagnosing and treating food-allergic patients. Previous
studies have shown that many high risk food-allergic
patients do not have an epinephrine auto-injector (EAI)
and that GPs are not always knowledgeable about these
patients. However, there are currently no data as to
whether GPs prescribe EAIs to high risk food-allergic
patients presenting to primary care practices. Therefore,
the aim of this study was to obtain information about
EAI prescriptions by GPs to food-allergic patients at
high risk for anaphylaxis in the Netherlands.
Methods
Patients aged 12-23 who consulted their GP for allergic
symptoms were identified in a primary care database
(2001-2012). Allergic symptoms were defined as ICPC-
codes A12 (allergy), T04/T05 (feeding problem infant/
child/adult) and EAI was defined as ATC-group
C01CA24 (epinephrine). Patients were classified as prob-
ably or unlikely to be food-allergic. A risk factor based
protocol was used to identify probably food-allergic
patients at high risk for anaphylaxis and to assess the
need for an EAI.
Results
Out of 1314 patients who consulted their GP for allergic
symptoms from 2001-2012, 148 patients (11.3%) con-
sulted their GP for allergic symptoms due to food.
Eighty patients were excluded from analyses due to
incomplete data. Therefore, 68 patients were eligible for
analysis. Thirty-four (50%) of these patients were classi-
fied as probably food-allergic and mostly reported symp-
toms from nuts (44.1%). Twenty-seven were considered
high risk patients and candidates for an EAI. Impor-
tantly, only 10 (37%) of them had actually been pre-
scribed an EAI.
Conclusions
Although previous studies have shown that some high
risk food-allergic patients do not seek medical care, this
study shows that even those that do visit their GPs are
often not prescribed an EAI. This shows that previously
identified low rates of EAI ownership are at least partly
due to failure by GPs to prescribe this medication to
patients for whom it would be appropriate to do so.
These data suggest that opportunities exist to improve
the quality of care for high risk food-allergic patients in
primary care.
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